<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389035</url>
  </required_header>
  <id_info>
    <org_study_id>FT01CARCIK</org_study_id>
    <nct_id>NCT03389035</nct_id>
  </id_info>
  <brief_title>Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT</brief_title>
  <acronym>CARCIK</acronym>
  <official_title>Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Matilde Tettamanti Menotti De Marchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Matilde Tettamanti Menotti De Marchi Onlus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum
      Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and
      pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT):</measure>
    <time_frame>1 month</time_frame>
    <description>rate and severity of the cytokine release syndrome (CRS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Lymphoblastic Leukemia, in Relapse</condition>
  <arm_group>
    <arm_group_label>CARCIK-CD19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CARCIK-CD19</intervention_name>
    <description>Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene</description>
    <arm_group_label>CARCIK-CD19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children (1-17) and adults (18-75 years old);

          -  Relapsed or refractory adult and pediatric B-cell precursor ALL after HSCT;

          -  Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow
             cytometry;

          -  Bone marrow with â‰¥ 5% lymphoblasts by morphologic assessment at screening;

          -  No evidence of overall aGVHD &gt; Grade I or chronic GVHD (cGVHD) greater than mild at
             time of enrollment and in the previous 30 days;

          -  No longer taking immunosuppressive agents for at least 30 days prior to enrollment;

        Exclusion Criteria:

          -  Patients with GVHD Grades II-IV;

          -  Any cell therapy in the last 30 days;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale PG23</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Segreteria Ematologia</last_name>
      <phone>+39035267</phone>
      <phone_ext>3684</phone_ext>
      <email>ematologiasegr@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Segreteria Direzione</last_name>
      <phone>+39039233</phone>
      <phone_ext>6816</phone_ext>
      <email>segreteriadirezionecp@fondazionembbm.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Biondi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>CAR-T</keyword>
  <keyword>CARCIK</keyword>
  <keyword>Transposon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

